In Real Life, Low-Level HER2 Expression May Be Associated With Better Outcome in HER2-Negative Breast Cancer: A Study of the National Cancer Center, China
Yiqun Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Binghe Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Peng Yuan, Jiayu Wang(Nanjing University of Chinese Medicine), Hongnan Mo(Chinese Academy of Medical Sciences & Peking Union Medical College), Nilupai Abudureheiyimu(Chinese Academy of Medical Sciences & Peking Union Medical College), Qiao Li(Guangzhou University of Chinese Medicine), Qing Li(Army Medical University), Shanshan Chen(Chongqing University of Posts and Telecommunications), Yang Luo(Chongqing University of Posts and Telecommunications), Yimeng Chen(Chinese Academy of Medical Sciences & Peking Union Medical College), Zijing Wang(Qingdao University), Pin Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Ying Fan(Chinese Academy of Medical Sciences & Peking Union Medical College), Shaoyan Lin(Nanjing Agricultural University), Xiuwen Guan(Chinese Academy of Medical Sciences & Peking Union Medical College), Ruigang Cai(Chinese Academy of Medical Sciences & Peking Union Medical College), Fei Ma(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cited by 119
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
|Annals of Oncology|2020|1.4k